Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CAR T cells have revolutionized the treatment of relapsed and refractory CD19-positive leukemia and lymphoma.
|
30680777 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
T cell immunotherapies are promising options in leukemia, among which the CD19/CD3-bispecific T cell engager antibody blinatumomab (MT103) has shown high response rates at very low doses in patients with lymphoma.
|
30611570 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Tisagenlecleucel (kymriah, Novartis) is an autologous CD19-targeted CAR T cell product approved for treatment of R/R B cell ALL and lymphoma.
|
30764841 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use.
|
30622115 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma.
|
30828333 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CD19-targeted CAR-T is an effective modality in treating refractory B-cell malignancies including leukemia and lymphoma.
|
28762313 |
2019 |
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL.
|
31446199 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.
|
31372000 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
|
31690821 |
2019 |
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19.
|
30841880 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma.
|
31847470 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma.
|
31429760 |
2019 |
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
|
31439577 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients.
|
30809033 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
About half the launches are expected to be in B-cell (CD-19) lymphomas and leukemias.
|
31198178 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma.
|
30198955 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has changed the typical outcomes of relapsed/refractory B-cell leukemia and lymphoma.
|
31611950 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas.
|
31482064 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clinically advanced form of ACT approved to date for the treatment of CD19-positive leukaemias and lymphomas.
|
30413825 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CD19 chimeric antigen receptor (CAR) T cell therapy has changed the outcomes of relapsed/refractory B‑cell leukemia and lymphoma.
|
30942469 |
2019 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.
|
29367945 |
2018 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
These data suggest that Igβ and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
|
29669863 |
2018 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Its most successful embodiment to date is based on the use of second-generation chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule found in most B-cell leukemias and lymphomas.
|
29358181 |
2018 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma.
|
29685162 |
2018 |
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We transduced CB-derived NK cells with a retroviral vector incorporating the genes for CAR-CD19, IL-15 and inducible caspase-9-based suicide gene (iC9), and demonstrated efficient killing of CD19-expressing cell lines and primary leukemia cells in vitro, with marked prolongation of survival in a xenograft Raji lymphoma murine model.
|
28725044 |
2018 |